A UK‑based company, Greywolf Therapeutics, has developed a new treatment called GRWD5769, which is showing encouraging results in early trials. The drug is designed to fight six types of cancer: bladder, cervix, lungs, intestines, throat, and head.
ALSO READ: Over 30,000 Rwandans Speak Fluent Chinese
Clinical Trial Results
GRWD5769 was tested on 83 patients. In 31% of cases, the cancer either shrank or stopped growing. Some patients experienced tumor reductions of up to 95%, a remarkable outcome for an early‑stage trial.
ALSO READ: Rwandan Peacekeepers Win Trophy in South Sudan
How the Drug Works
The medicine is taken as tablets in the morning and evening. It works by making cancer cells visible to the body’s immune system, which normally fails to detect them. Combined with other therapies that boost immune strength, the body itself is enabled to fight the disease.
Expert Insights
Stefan Symeonides, who led the clinical trial, explained: “The advantage of this drug is that it enables the immune system to recognize hidden cancers and fight them directly, rather than relying solely on medication to do the work.”
Next Steps
The drug will now move into further testing phases before it can be approved for medical use. Researchers believe it could be significant, as more than 20 million people worldwide are diagnosed with various cancers each year.
Global Impact
This development highlights the potential of biotechnology to expand treatment options and strengthen the global fight against cancer. If successful, GRWD5769 could become a vital addition to cancer therapies, offering hope to millions of patients.
